T-Oligo induces apoptosis in advanced prostate cancer cells

Oligonucleotides

Volumn 19, Issue 3, 2009, Pages 287-291

  Gnanasekar, Munirathinam ^a   Thirugnanam, Sivasakthivel ^a   Zheng, Guoxing ^a   Chen, Aoshuang ^a   Ramaswamy, Kalyanasundaram ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; OLIGONUCLEOTIDE; T OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; OLIGODEOXYRIBONUCLEOTIDES; PROSTATIC NEOPLASMS; TELOMERE;

EID: 70349290975     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0179     Document Type: Article

References (27)

1. AOKI, H., IWADO, E., ELLER, M.S., KONDO, Y., FUJIWARA, K., LI, G.Z., HESS, K.R., SIWAK, D.R., SAWAYA, R., MILLS, G.B., GILCHREST, B.A., and KONDO, S. (2007). Telomere 3′ overhang-specif c DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. 21, 2918-2930.
2. ARAGON-CHING, J.B., and DAHUT, W.L. (2007). Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther. 5A, 151-160.
3. BOOKSTEIN, R., RIO, P., MADREPERLA, S.A., HONG, F., ALLRED, C., GRIZZLE, W.E., and LEE, W.H. (1990). Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA. 87, 7762-7766.
4. BROCCOLI, D., SMOGORZEWSKA, A., CHONG, L., and DE LANGE, T. (1997). Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat. Genet. 17, 231-235.
5. CARROLL, A.G., VOELLER, H.J., SUGARS, L., and GELMANN, E.P. (1993). p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23, 123-134.
6. CHAKRABORTY, M., QIU, S.G., VASUDEVAN, K.M., and RANGNEKAR, V.M. (2001). Par-4 drives traff cking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61, 7255-7263.
7. CRUZ, P.D., JR., LEVERKUS, M., DOUGHERTY, I., GLEASON, M.J., ELLER, M., YAAR, M., and GILCHREST, B.A. (2000). Thymidine dinucleotides inhibit contact hypersensitivity and activate the gene for tumor necrosis factor alpha1. J. Invest. Dermatol. 114, 253-258.
8. ELLER, M.S., LI, G.Z., FIROOZABADI, R., PURI, N., and GILCHREST, B.A. (2003). Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3′ overhang specif c DNA. FASEB J. 17, 152-162.
9. ELLER, M.S., PURI, N., HADSHIEW, I.M., VENNA, S.S., and GILCHREST, B.A. (2002). Induction of apoptosis by telomere 3′ overhang-specif c DNA. Exp. Cell Res. 276, 185-193.
10. HADSHIEW, I.M., ELLER, M.S., GASPARRO, F.P., and GILCHREST, B.A. (2001). Stimulation of melanogenesis by DNA oligonucle-otides: effect of size, sequence and 5′ phosphorylation. J. Invest. Dermatol. 25, 127-138.
11. HARRINGTON, L., MCPHAIL, T., MAR, V., ZHOU, W., OULTON, R., BASS, M.B., ARRUDA, I., and ROBINSON, M.O. (1997). A mammalian telomerase-associated protein. Science. 275, 973-977.
12. JEMAL, A., SIEGEL, R., WARD, E., HAO, Y., XU, J., MURRAY, T., and THUN, M.J. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96.
13. KARLSEDER, J., BROCCOLI, D., DAI, Y., HARDY, S., and DE LANGE, T. (1999). p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283, 1321-1325.
14. LEITH, J.T. (1994). In vitro radiation sensitivity of the LNCaP pros-tatic tumor cell line. Prostate. 24, 119-124.
15. LI, G.Z., ELLER, M.S., FIROOZABADI, R., and GILCHREST, B.A. (2003). Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc. Natl. Acad. Sci. USA. 100, 527-531.
16. LI, G.Z., ELLER, M.S., HANNA, K., and GILCHREST, B.A. (2004). Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Exp. Cell Res. 301, 189-200.
17. LONGE, H., FALLER, D., and DENIS, G. (2005). Telomere-based pre-clinical therapy in a murine model of non-Hodgkin's lymphoma of the diffuse large B cell (DLCL) type. Blood. 106, 607.
18. LONGE, H.O., ROMESSER, P.B., RANKIN, A.M., FALLER, D.V., ELLER, M.S., GILCHREST, B.A., and DENIS, G.V. (2009). Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int. J. Cancer. 124, 473-482.
19. OHASHI, N., YAAR, M., ELLER, M.S., TRUZZI, F., and GILCHREST, B.A. (2007). Features that determine telomere homolog oligonu-cleotide-induced therapeutic DNA damage-like responses in cancer cells. J. Cell. Physiol. 210, 582-595.
20. PETRYLAK, D. (2005). Therapeutic options in androgen-indepen-dent prostate cancer: building on docetaxel. BJU. Int. 96 (Suppl. 2), 41-46.
21. PURI, N., ELLER, M.S., BYERS, H.R., DYKSTRA, S., KUBERA, J., and GILCHREST, B.A. (2004). Telomere-based DNA damage responses: a new approach to melanoma. FASEB J. 18, 1373-1381.
22. STAMBOLIC, V., SUZUKI, A., DE LA POMPA, J.L., BROTHERS, G.M., MIRTSOS, C., SASAKI, T., RULAND, J., PENNINGER, J.M., SIDEROVSKI, D.P., and MAK, T.W. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95, 29-39.
23. TAKAHASHI, H., FUKUTOME, K., WATANABE, M., FURUSATO, M., SHIRAISHI, T., ITO, H., SUZUKI, H., IKAWA, S., and HANO, H. (2001). Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate. 47, 85-90.
24. VLIETSTRA, R.J., VAN ALEWIJK, D.C., HERMANS, K.G., VAN STEENBRUGGE, G.J., and TRAPMAN, J. (1998). Frequent inac-tivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58, 2720-2723.
25. YAAR, M., ELLER, M.S., PANOVA, I., KUBERA, J., WEE, L.H., COWAN, K.H., and GILCHREST, B.A. (2007). Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 9, R13.
26. YU, C.H., KAN, S.F., PU, H.F., JEA CHIEN, E., and WANG, P.S. (2008). Apoptotic signaling in bufalin-and cinobufagin-treated androgen-dependent and-independent human prostate cancer cells. Cancer Sci. 99, 2467-2476.
27. YUAN, X.J., and WHANG, Y.E. (2002). PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 21, 319-327.